Literature DB >> 15671364

Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: demonstration of diurnal variation in lesion size.

Nilo A Avila1, Andrew J Dwyer, Diane V Murphy-Johnson, Pamela Brooks, Joel Moss.   

Abstract

OBJECTIVE: Our aims were to define the sonographic features of abdominal and pelvic lymphangioleiomyomas in lymphangioleiomyomatosis (LAM) and to evaluate the utility of sonography in visualizing diurnal change in the size of the masses.
MATERIALS AND METHODS: Forty-four patients with LAM and abdominal and pelvic lymphangioleiomyomas found on screening CT underwent sonography. Twenty-two patients had two studies on the same day, one in the morning and the other late in the afternoon.
RESULTS: Forty-nine masses were scanned in the 44 patients. The anatomic distribution of the masses was the following: retroperitoneal (29/44 patients, 66%), pelvic (10/44, 23%), and both retroperitoneal and pelvic (5/44, 11%). Of the 49 masses, 12 (24%) were cystic, 16 (33%) were solid, and 21 (43%) were complex. Twenty-two patients underwent sonography in the morning and afternoon. The masses increased in size between the two studies in all 21 patients in whom the masses were visualized in both studies. In three of 21 patients, the echotexture of the masses changed between the morning and afternoon studies: In two the echotexture changed from solid to complex, and in the other, it changed from hyperechoic to isoechoic relative to the liver.
CONCLUSION: The sonographic characteristics of lymphangioleiomyomas are similar to some neoplasms such as lymphoma and ovarian cancer (a similarity that sometimes prompts biopsy). After a mass is shown in a patient with LAM, repeat sonography in the morning and afternoon is useful to depict diurnal variation in size and echotexture and to confirm the diagnosis of lymphangioleiomyoma and avoid biopsy.

Entities:  

Mesh:

Year:  2005        PMID: 15671364     DOI: 10.2214/ajr.184.2.01840459

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 2.  Imaging features of lymphangioleiomyomatosis: diagnostic pitfalls.

Authors:  Nilo A Avila; Andrew J Dwyer; Joel Moss
Journal:  AJR Am J Roentgenol       Date:  2011-04       Impact factor: 3.959

3.  Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Thomas Shawker; Connie G Glasgow; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

4.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

5.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

6.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

Review 7.  Lymphatic involvement in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo M Taveira-Dasilva; Thomas N Darling; Joel Moss
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 8.  Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis.

Authors:  Connie G Glasgow; Souheil El-Chemaly; Joel Moss
Journal:  Eur Respir Rev       Date:  2012-09-01

9.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

10.  Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going.

Authors:  Angelo M Taveira-Dasilva; Wendy K Steagall; Joel Moss
Journal:  F1000 Med Rep       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.